【制药网 政策法规】10 月 28 日，国家卫健委正式发布《关于第四批鼓励仿制药品建议目录的公示》，将贝沙罗汀、地夫可特、普鲁士蓝等 21 个药品纳入其中，公示期为 5 个工作日。作为药品供应保障体系的重要组成部分，仿制药在填补临床用药空白、提高药品可及性、降低医疗支出等方面发挥着不可替代的作用。此前，国家已先后发布三批鼓励仿制药物目录，共纳入 89 个品种，其中第一批 33 个品种、第二批 17...
Source Link【制药网 政策法规】10 月 28 日，国家卫健委正式发布《关于第四批鼓励仿制药品建议目录的公示》，将贝沙罗汀、地夫可特、普鲁士蓝等 21 个药品纳入其中，公示期为 5 个工作日。作为药品供应保障体系的重要组成部分，仿制药在填补临床用药空白、提高药品可及性、降低医疗支出等方面发挥着不可替代的作用。此前，国家已先后发布三批鼓励仿制药物目录，共纳入 89 个品种，其中第一批 33 个品种、第二批 17...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.